CSPCY (CSPC Pharmaceutical Group) Other Current Assets: $157 Mil (As of Dec. 2025)


CSPCY CSPC Pharmaceutical Group Ltd CSPCY
74 GF Score
Price $4.17
GF Value $3.37
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is CSPC Pharmaceutical Group Other Current Assets?

CSPC Pharmaceutical Group CSPCY +4.25% 74 Other Current Assets is $157 Mil as of Dec. 2025. GuruFocus rates CSPCY with a GF Score™ of 74/100 and a GF Value™ of $3.37 (Modestly Overvalued). The stock has 4 warning signs investors should review.

CSPC Pharmaceutical Group's other current assets for the quarter that ended in Dec. 2025 was $157 Mil.

CSPC Pharmaceutical Group's quarterly other current assets declined from Jun. 2025 ($83 Mil) to Sep. 2025 ($0 Mil) but then increased from Sep. 2025 ($0 Mil) to Dec. 2025 ($157Mil).

CSPC Pharmaceutical Group's annual other current assets increased from Dec. 2023 ($54 Mil) to Dec. 2024 ($78 Mil) increased from Dec. 2024 ($78 Mil) to Dec. 2025 ($157 Mil).


CSPC Pharmaceutical Group Other Current Assets Related Terms


CSPC Pharmaceutical Group Other Current Assets Historical Data

* Premium members only.

The historical data trend for CSPC Pharmaceutical Group's Other Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CSPC Pharmaceutical Group Other Current Assets Chart

CSPC Pharmaceutical Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -0.00 53.99 78.21 157.22

CSPC Pharmaceutical Group Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 83.13 0.00 157.22 0.00
CSPCY
74GF Score
CSPC Pharmaceutical Group Ltd CSPCY
Other Current Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CSPC Pharmaceutical Group Other Current Assets Calculation

Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:


Cash
Trade Receivables
Inventory

The assets grouped under other current assets are most commonly:


Prepaid Expenses
Tax Assets
Non-Trade Receivables
Other (too numerous to list)

Some companies can and do choose to report each of these items separately.

Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.

Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.

Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.

Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.

There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.

At most companies, other current assets are a small and unimportant part of the total balance sheet.

Frequently Asked Questions Learn more about Other Current Assets →
What does a Other Current Assets of $157 Mil mean?
CSPC Pharmaceutical Group (CSPCY) has a Other Current Assets of $157 Mil as of Dec. 2025. Other current assets as record on a company's balance sheet not categorized as standard assets. View historical data on CSPC Pharmaceutical Group.
Is CSPC Pharmaceutical Group's Other Current Assets too high?
CSPC Pharmaceutical Group's current Other Current Assets is $157 Mil. Overall, CSPC Pharmaceutical Group has a GF Score™ of 74/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CSPC Pharmaceutical Group's Other Current Assets compare to LLY and JNJ?
CSPC Pharmaceutical Group's Other Current Assets of $157 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Assets for a Drug Manufacturers company?
A good Other Current Assets depends on the Drug Manufacturers industry context. However, Other Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Assets mean?
A high Other Current Assets can signal that a stock is expensive relative to its fundamentals. Other current assets as record on a company's balance sheet not categorized as standard assets. View historical data on CSPC Pharmaceutical Group. CSPC Pharmaceutical Group's current Other Current Assets is $157 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CSPC Pharmaceutical Group stock overvalued right now?
Based on GuruFocus' analysis, CSPC Pharmaceutical Group (CSPCY) is currently considered Modestly Overvalued. The stock's GF Value™ is $3.37, compared to a current price of $4.17 — trading 23.7% above its estimated fair value. The current Other Current Assets is $157 Mil. CSPC Pharmaceutical Group's overall GF Score™ is 74/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Assets calculated?
Other Current Assets is calculated from a company's financial statements. For CSPC Pharmaceutical Group (CSPCY), the current Other Current Assets is $157 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CSPC Pharmaceutical Group (CSPCY) Overvalued in 2026?

Based on GuruFocus' analysis, CSPC Pharmaceutical Group stock appears to be overvalued. The current stock price of $4.17 is trading 23.7% above its estimated GF Value™ of $3.37. GuruFocus considers CSPC Pharmaceutical Group to be Modestly Overvalued.

Key valuation signals for CSPCY:

  • Other Current Assets: $157 Mil
  • GF Value™: $3.37 vs. price of $4.17 (23.7% above fair value)
  • GF Score™: 74/100 with 4 warning signs

No single metric tells the full story. See the CSPCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


CSPC Pharmaceutical Group Business Description

Address No.896 Zhongshandong Street, Gaoxin District, Hebei Province, Shijiazhuang, CHN, 050035
CSPC Pharmaceutical Group LTD is engaged in the manufacture and sale of pharmaceutical products. The group's segments include: Finished drugs, consisting research and development, manufacture and sale of pharmaceutical products and license fee income; Bulk products, that manufacture and sale of vitamin C, and antibiotic products in bulk powder form; and Functional food and others, that manufacture and sale of functional food products (including caffeine food additives, anhydrous glucose, acarbose and vitamin C buccal tablets), provision of healthcare service and others. It derives maximum revenue from Finished Products segments. Geographically, the company operates in Chinese Mainland, which Chinese Mainland generates maximum revenue; Other Asian regions; Europe; North America; and Others.
74GF Score

Get the complete analysis for CSPCY

Other Current Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.17
Price
$3.37
GF Value